Multiple Myeloma

Daratumumab Boosts Outcomes in Newly Diagnosed Multiple Myeloma

(Medscape Medical News) June 17, 2019 - Adding daratumumab (Darzalex, Janssen) to standard-of-care therapy for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant (ASCT) significantly improves responses without compromising safety, according to new findings from the phase 3 CASSIOPEIA trial.

read article (free registration required)

New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

(Oncopeptides) June 16, 2019 - Oncopeptides AB announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial.

read corporate press release

Roswell Park Physician Leads Development of New Multiple Myeloma Imaging Guidelines

(RPCCC) June 13, 2019 - International Myeloma Working Group shares recommendations for plasma-cell disorders.

read press release

Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

(Yahoo! Finance) June 14, 2019 - Bristol-Myers Squibb Company today announced the presentation of updated data from ELOQUENT-3, the international randomized Phase 2 study evaluating Empliciti (elotuzumab) plus pomalidomide and dexamethasone (EPd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM). In a non-prespecified analysis conducted to provide a descriptive assessment of overall survival (OS) after extended follow-up of at least 18.3 months, patients treated with EPd continued to experience sustained and clinically relevant OS and progression-free survival (PFS) benefits compared with patients treated with Pd.

read article

Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting

(Karyopharm) June 14, 2019 - Once weekly oral selinexor in combination with Kyprolis® and low dose dexamethasone demonstrates 78% ORR in patients with heavily pretreated, Kyprolis-naïve multiple myeloma.

read corporate press release

Cardiac Toxicity Risk Factors Identified With Relapsed Multiple Myeloma Therapy

(Vanderbilt University) June 13, 2019 - More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in Journal of Clinical Oncology.

read article

Multiple Myeloma Research Foundation (MMRF) Launches CureCloud™ to Advance Precision Medicine

(Yahoo! Finance) June 12, 2019 - The MMRF CureCloud will be the first and most comprehensive data hub in multiple myeloma designed to speed the delivery of precision-based treatment to every patient.

read article

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

(Genmab) June 11, 2019 - Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s proprietary HexaBody technology. New agreement builds on Genmab’s successful DARZALEX® collaboration with Janssen. Next-generation HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications.

read corporate press release

J&J Takes Option on Genmab Follow-Up to Darzalex

(PMLiVE [UK]) June 11, 2019 - Johnson & Johnson’s longstanding alliance with Genmab has already produced one blockbuster drug for lymphoma – Darzalex – and it is now eyeing a follow-up candidate. The US company’s Janssen Biotech unit has signed an option agreement with Genmab for HexaBody-CD38, billed as a “next-generation” antibody that targets the same CD38 protein as Darzalex (daratumumab) which is approved to treat multiple myeloma and made more than $2bn in sales last year.

read article

Janssen to Present Data from its Robust Oncology Portfolio and Pipeline at the 24th EHA Annual Congress

(Yahoo! Finance) June 10, 2019 - Results from DARZALEX® (daratumumab) Phase 3 CASSIOPEIA study in newly diagnosed transplant eligible patients with multiple myeloma selected for the Presidential Symposium. Final analysis of Phase 3 IMBRUVICA® (ibrutinib) RESONATE(TM)-2 study with five-year follow-up data in previously untreated patients with chronic lymphocytic leukaemia.

read article

Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

(Takeda) June 5, 2019 – Takeda Pharmaceutical Company Limited today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with NINLAROTM (ixazomib) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care regimens. As a result of this analysis, Takeda has decided to discontinue the trial.

read corporate press release

Setback for Takeda As Ninlaro Flunks Amyloidosis Trial

(PMLiVE [UK]) June 6, 2019 - Takeda’s attempts to extend the uses of its multiple myeloma therapy Ninlaro into new disease areas have been hit by a failed phase 3 trial in amyloid light-chain amyloidosis (AL). Ninlaro (ixazomib) plus dexamethasone failed to achieve a significant increase in overall haematological response compared to physician’s choice treatment in the TOURMALINE-AL1 trial, which involved patients with relapsed or refractory AL – also known as primary amyloidosis.

read article

Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients

(The Street) June 5, 2019 - Amgen releases data from its phase 1 study on an investigational bispecific T cell engager molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma. Shares of Amgen could face negative pressure Wednesday after the company released data from its phase 1 study on an investigational bispecific T cell engager molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma.

read article

Study Finds Drug Therapy Can Delay Onset Of Myeloma Symptoms

(Mayo Clinic) June 3, 2019 - The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers.

read press release

Janssen Presents Positive Darzalex Results At ASCO

(PharmaTimes [UK]) June 3, 2019 - Janssen Oncology has announced key data on Darzalex (daratumumab) for multiple myeloma at this year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

read article

Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma

(2019 ASCO) June 2, 2019 – A new study analyzing demographic statistics from the National Cancer Database identified multiple socio-economic factors, including private insurance, living in a regionally higher-income area, and receiving treatment in certain practice settings as being associated with longer survival for patients with multiple myeloma. Furthermore, researchers found that neither race (black or white) nor gender had a significant impact on survival. The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

read press release

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

(Amgen) June 2, 2019 - Updated Phase 1 data of investigational AMG 420 in relapsed and/or refractory multiple myeloma highlighted in oral presentation and accepted for best of ASCO®.

read corporate press release

Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019

(Associated Press) June 2, 2019 - Celgene Corporation today announced the first clinical results evaluating iberdomide (CC-220) in combination with dexamethasone in patients with relapsed and refractory multiple myeloma from the ongoing phase 1/2 CC-220-MM-001 study during an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

read article

Phase 3 Trial Of Isatuximab Combination Therapy Showed 40% Reduction In The Risk Of Disease Progression Or Death For Patients With Relapsed/Refractory Multiple Myeloma

(Morningstar) June 2, 2019 - Isatuximab, an investigational anti-CD38 monoclonal antibody, added to pomalidomide and dexamethasone prolonged progression free survival by 5 months compared to pomalidomide and dexamethasone alone (11.53 vs.6.47 months, p=0.001, HR 0.596).

read article

Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

(Janssen) June 2, 2019 - New formulation also showed shorter administration time and lower rate of infusion-related reactions.

read corporate press release
Next Page